NR1I2 and inflammatory bowel disease: Specifically, PXR activation by a gut-specific PXR agonist rifaximin regulates the expression of genes responsible for the metabolism of inflammatory mediators and, in doing so, helps to quell the excessive immune responses that underlie IBD pathogenesis [67,68,88,89,90,91].